Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | MMP12 | P39900 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103351 | 1.00 | FKBP1A (0.47) | FKBP1AALDH1A1KDM4EMMP8MMP12 | |
| SCHEMBL3429323 | 0.91 | ALDH1A1 (0.43) | FKBP1AALDH1A1KDM4EMMP8MMP12 | |
| SCHEMBL3429330 | 0.91 | ALDH1A1 (0.43) | FKBP1AALDH1A1KDM4EMMP8MMP12 | |
| SCHEMBL26212073 | 0.90 | FKBP1A (0.51) | FKBP1AALDH1A1MMP8MMP12MMP13 | |
| SCHEMBL3256301 | 0.89 | FKBP1A (0.56) | FKBP1AALDH1A1MMP8MMP12MMP13 | |
| SCHEMBL3256303 | 0.89 | FKBP1A (0.56) | FKBP1AALDH1A1MMP8MMP12MMP13 | |
| SCHEMBL7305308 | 0.87 | POLB (0.48) | ALDH1A1KDM4EMMP8MMP12MMP13 | |
| SCHEMBL6830973 | 0.87 | FKBP1A (0.58) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6830972 | 0.87 | FKBP1A (0.58) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6831371 | 0.83 | FKBP1A (0.54) | FKBP1AALDH1A1MMP8MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | FKBP1A 289/4885ALDH1A1 3279/4885KDM4E 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.